HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma.

AbstractPURPOSE:
Natural killer (NK) cells play a critical role in tumor immunosurveillance. Multiple activating and inhibitory receptors (IR) regulate NK-cell-mediated tumor control. The IR T-cell immunoglobulin and ITIM domain (TIGIT) and its counter-receptor CD226 exert opposite effects on NK-cell-mediated tumor reactivity.
EXPERIMENTAL DESIGN:
We evaluated the frequency, phenotype, and functions of NK cells freshly isolated from healthy donors and patients with melanoma with multiparameter flow cytometry. We assessed TIGIT and CD226 cell surface expression and internalization upon binding to CD155. We evaluated the role of IL15 and TIGIT blockade in increasing NK-cell-mediated cytotoxicity in vitro and in two mouse models.
RESULTS:
NK cells are present at low frequencies in metastatic melanoma, are dysfunctional, and downregulate both TIGIT and CD226 expression. As compared with TIGIT- NK cells, TIGIT+ NK cells exhibit higher cytotoxic capacity and maturation, but paradoxically lower cytotoxicity against CD155+ MHC class I-deficient melanoma cells. Membrane bound CD155 triggers CD226 internalization and degradation, resulting in decreased NK-cell-mediated tumor reactivity. IL15 increases TIGIT and CD226 gene expression by tumor-infiltrating NK cells (TiNKs) and, together with TIGIT blockade, increases NK-cell-mediated melanoma cytotoxicity in vitro and decreases tumor metastasis in two mouse melanoma models. Specific deletion of TIGIT on transferred NK cells enhances the antimetastatic activity of IL15, while CD226 blockade decreases the effects of IL15 and TIGIT blockade.
CONCLUSIONS:
Our findings support the development of novel combinatorial immunotherapy with IL15 and TIGIT blockade to promote NK-cell-mediated destruction of MHC class I-deficient melanoma, which are refractory to CD8+ T-cell-mediated immunity.See related commentary by Pietra et al., p. 5274.
AuthorsJoe-Marc Chauvin, Mignane Ka, Ornella Pagliano, Carmine Menna, Quanquan Ding, Richelle DeBlasio, Cindy Sanders, Jiajie Hou, Xian-Yang Li, Soldano Ferrone, Diwakar Davar, John M Kirkwood, Robert J Johnston, Alan J Korman, Mark J Smyth, Hassane M Zarour
JournalClinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res) Vol. 26 Issue 20 Pg. 5520-5533 (10 15 2020) ISSN: 1557-3265 [Electronic] United States
PMID32591463 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Copyright©2020 American Association for Cancer Research.
Chemical References
  • Antigens, Differentiation, T-Lymphocyte
  • CD226 antigen
  • Interleukin-15
  • Receptors, Immunologic
  • Receptors, Virus
  • TIGIT protein, human
  • poliovirus receptor
Topics
  • Animals
  • Antigens, Differentiation, T-Lymphocyte (genetics, immunology)
  • CD8-Positive T-Lymphocytes (drug effects, immunology)
  • Cell Line, Tumor
  • Cell Proliferation (drug effects)
  • Humans
  • Interleukin-15 (genetics, pharmacology)
  • Killer Cells, Natural (drug effects, immunology)
  • Melanoma (blood, genetics, immunology, pathology)
  • Mice
  • Receptors, Immunologic (antagonists & inhibitors, genetics)
  • Receptors, Virus (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: